Favorable outcomes of patients with sickle cell disease hospitalized due to COVID‑19: A report of three cases

Tentolouris,Anastasios; Stafylidis,Christos; Siafarikas,Christos; Dimopoulou,Maria N.; Makrodimitri,Sotiria; Bousi,Stelios; Papalexis,Petros; Damaskos,Christos; Trakas,Nikolaos; Sklapani,Pagona; Spandidos,Demetrios A.; Georgakopoulou,Vasiliki Epameinondas

doi:10.3892/etm.2022.11268

Favorable outcomes of patients with sickle cell disease hospitalized due to COVID‑19: A report of three cases

Authors:
- Anastasios Tentolouris
- Christos Stafylidis
- Christos Siafarikas
- Maria N. Dimopoulou
- Sotiria Makrodimitri
- Stelios Bousi
- Petros Papalexis
- Christos Damaskos
- Nikolaos Trakas
- Pagona Sklapani
- Demetrios A. Spandidos
- Vasiliki Epameinondas Georgakopoulou
View Affiliations

Affiliations: First Department of Propedeutic and Internal Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece, First Department of Internal Medicine, Laiko General Hospital, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece, Hemoglobinopathies Reference Center, Laiko General Hospital, 11527 Athens, Greece, Department of Infectious Diseases‑COVID‑19 Unit, Laiko General Hospital, 11527 Athens, Greece, Renal Transplantation Unit, Laiko General Hospital, 11527 Athens, Greece, Unit of Endocrinology, First Department of Internal Medicine, Laiko General Hospital, National and Kapodistrian University of Athens, 11527 Athens, Greece, Department of Biochemistry, Sismanogleio Hospital, 15126 Athens, Greece, Department of Cytology, Mitera Hospital, 15123 Athens, Greece, Laboratory of Clinical Virology, School of Medicine, University of Crete, 71003 Heraklion, Greece
Published online on: March 21, 2022 https://doi.org/10.3892/etm.2022.11268
Article Number: 338
Copyright: © Tentolouris et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Sickle cell disease (SCD) is one of the most frequent and severe monogenic disorders, affecting millions of individuals worldwide. SCD represents a fatal hematological illness, characterized by veno‑occlusive events and hemolytic anemia. Hemolytic anemia is caused by abnormal sickle‑shaped erythrocytes, which induce parenchymal destruction and persistent organ damage, resulting in considerable morbidity and mortality. During the coronavirus disease 2019 (COVID‑19) pandemic, patients with SCD were characterized as a ‘high‑risk’ group due to their compromised immune system, caused by functional hyposplenism, as well as systemic vasculopathy. COVID‑19 is characterized by endothelial damage and a procoagulant condition. The present study describes the clinical features, management and outcomes of 3 patients with SCD who were hospitalized due to COVID‑19, who all had favorable outcomes despite the complications.

View Figures

View References

1	Aygun B and Odame I: A global perspective on sickle cell disease. Pediatr Blood Cancer. 59:386–390. 2012.PubMed/NCBI View Article : Google Scholar
2	Ware RE, de Montalembert M, Tshilolo L and Abboud MR: Sickle cell disease. Lancet. 390:311–323. 2017.PubMed/NCBI View Article : Google Scholar
3	Shet AS, Lizarralde-Iragorri MA and Naik RP: The molecular basis for the prothrombotic state in sickle cell disease. Haematologica. 105:2368–2379. 2020.PubMed/NCBI View Article : Google Scholar
4	Glassberg J: Evidence-based management of sickle cell disease in the emergency department. Emerg Med Pract. 13:1–20; quiz 20. 2011.PubMed/NCBI
5	Paul RN, Castro OL, Aggarwal A and Oneal PA: Acute chest syndrome: Sickle cell disease. Eur J Haematol. 87:191–207. 2011.PubMed/NCBI View Article : Google Scholar
6	Vichinsky EP, Neumayr LD, Earles AN, Williams R, Lennette ET, Dean D, Nickerson B, Orringer E, McKie V, Bellevue R, et al: Causes and outcomes of the acute chest syndrome in sickle cell disease. National acute chest syndrome study group. N Engl J Med. 342:1855–1865. 2000.PubMed/NCBI View Article : Google Scholar
7	McCloskey KA, Meenan J, Hall R and Tsitsikas DA: COVID-19 infection and sickle cell disease: A UK centre experience. Br J Haematol. 190:e57–e58. 2020.PubMed/NCBI View Article : Google Scholar
8	Beerkens F, John M, Puliafito B, Corbett V, Edwards C and Tremblay D: COVID-19 pneumonia as a cause of acute chest syndrome in an adult sickle cell patient. Am J Hematol. 95:E154–E156. 2020.PubMed/NCBI View Article : Google Scholar
9	Giannis D, Ziogas IA and Gianni P: Coagulation disorders in coronavirus infected patients: COVID-19, SARS-CoV-1, MERS-CoV and lessons from the past. J Clin Virol. 127(104362)2020.PubMed/NCBI View Article : Google Scholar
10	Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS, Mehra MR, Schuepbach RA, Ruschitzka F and Moch H: Endothelial cell infection and endotheliitis in COVID-19. Lancet. 395:1417–1418. 2020.PubMed/NCBI View Article : Google Scholar
11	White RH and Keenan CR: Effects of race and ethnicity on the incidence of venous thromboembolism. Thromb Res. 123 (Suppl 4):S11–S17. 2009.PubMed/NCBI View Article : Google Scholar
12	Teulier M, Elabbadi A, Gerotziafas G, Lionnet F, Voiriot G and Fartoukh M: Severe COVID-19 with acute respiratory distress syndrome (ARDS) in a sickle cell disease adult patient: Case report. BMC Pulm Med. 21(46)2021.PubMed/NCBI View Article : Google Scholar
13	Silva-Pinto AC, Santos-Oliveira L, Santos FLS, Kashima Haddad S, De Santis GC and do Tocantins Calado R: COVID-19 infection in sickle cell patients in a developing Country: A case series. Acta Haematol. 145:1–4. 2022.PubMed/NCBI View Article : Google Scholar
14	Hussain FA, Njoku FU, Saraf SL, Molokie RE, Gordeuk VR and Han J: COVID-19 infection in patients with sickle cell disease. Br J Haematol. 189:851–852. 2020.PubMed/NCBI View Article : Google Scholar
15	Arlet JB, de Luna G, Khimoud D, Odièvre MH, de Montalembert M, Joseph L, Chantalat-Auger C, Flamarion E, Bartolucci P, Lionnet F, et al: Prognosis of patients with sickle cell disease and COVID-19: A French experience. Lancet Haematol. 7:e632–e634. 2020.PubMed/NCBI View Article : Google Scholar
16	Balanchivadze N, Kudirka AA, Askar S, Almadhoun K, Kuriakose P, Fadel R and Dabak V: Impact of COVID-19 infection on 24 patients with sickle cell disease. One center urban experience, Detroit, MI, USA. Hemoglobin. 44:284–289. 2020.PubMed/NCBI View Article : Google Scholar
17	Chen-Goodspeed A and Idowu M: COVID-19 presentation in patients with sickle cell disease: A case series. Am J Case Rep. 22(e931758)2021.PubMed/NCBI View Article : Google Scholar
18	Telfer P, De la Fuente J, Sohal M, Brown R, Eleftheriou P, Roy N, Piel FB, Chakravorty S, Gardner K, Velangi M, et al: Real-time national survey of COVID-19 in hemoglobinopathy and rare inherited anemia patients. Haematologica. 105:2651–2654. 2020.PubMed/NCBI View Article : Google Scholar
19	Arlet JB, Lionnet F, Khimoud D, Joseph L, de Montalembert M, Morisset S, Garou A, Cannas G, Cougoul P, Guitton C, et al: Risk factors for severe COVID-19 in hospitalized sickle cell disease patients: A study of 319 patients in France. Am J Hematol. 97:E86–E91. 2022.PubMed/NCBI View Article : Google Scholar
20	Panepinto JA, Brandow A, Mucalo L, Yusuf F, Singh A, Taylor B, Woods K, Payne AB, Peacock G and Schieve LA: Coronavirus disease among persons with sickle cell disease, United States, March 20-May 21, 2020. Emerg Infect Dis. 26:2473–2476. 2020.PubMed/NCBI View Article : Google Scholar
21	Minniti CP, Zaidi AU, Nouraie M, Manwani D, Crouch GD, Crouch AS, Callaghan MU, Carpenter S, Jacobs C, Han J, et al: Clinical predictors of poor outcomes in patients with sickle cell disease and COVID-19 infection. Blood Adv. 5:207–215. 2021.PubMed/NCBI View Article : Google Scholar
22	Singh A, Brandow AM and Panepinto JA: COVID-19 in individuals with sickle cell disease/trait compared with other Black individuals. Blood Adv. 5:1915–1921. 2021.PubMed/NCBI View Article : Google Scholar
23	Clift AK, Saatci D, Coupland CAC, Dambha-Miller H and Hippisley-Cox J: International Investigator Group for Ethnicity and COVID-19. Sickle cell disorders and severe COVID-19 outcomes: A cohort study. Ann Intern Med. 174:1483–1487. 2021.PubMed/NCBI View Article : Google Scholar
24	Mucalo L, Brandow AM, Dasgupta M, Mason SF, Simpson PM, Singh A, Taylor BW, Woods KJ, Yusuf FI and Panepinto JA: Comorbidities are risk factors for hospitalization and serious COVID-19 illness in children and adults with sickle cell disease. Blood Adv. 5:2717–2724. 2021.PubMed/NCBI View Article : Google Scholar
25	Menapace LA and Thein SL: COVID-19 and sickle cell disease. Haematologica. 105:2501–2504. 2020.PubMed/NCBI View Article : Google Scholar
26	Griffin JB, Haddix M, Danza P, Fisher R, Koo TH, Traub E, Gounder P, Jarashow C and Balter S: SARS-CoV-2 infections and hospitalizations among persons aged ≥16 Years, by vaccination status-los angeles county, California, May 1-July 25, 2021. MMWR Morb Mortal Wkly Rep. 70:1170–1176. 2021.PubMed/NCBI View Article : Google Scholar
27	Jan H, Waheeb A, AlAhwal H, Almohammadi A, Al-Marzouki A, Barefah A, Bahashawan S and Radhwi O: COVID-19 vaccine perception and hesitancy among patients with sickle cell disease in the western region of Saudi Arabia. Cureus. 14(e21026)2022.PubMed/NCBI View Article : Google Scholar
28	Guillon P, Clément M, Sébille V, Rivain JG, Chou CF, Ruvoën-Clouet N and Le Pendu J: Inhibition of the interaction between the SARS-CoV spike protein and its cellular receptor by anti-histo-blood group antibodies. Glycobiology. 18:1085–1093. 2008.PubMed/NCBI View Article : Google Scholar